NUP214 and Alzheimer disease: Thus, this highlights that selective CaN inhibition carried out by FK506 treatment has a potential restorative effect on TauO-driven toxicity and makes this FDA-approved immunosuppressant drug a valid candidate to counteract TauO-induced synaptic dysfunction at the basis of AD neuronal degeneration.